Sana Biotechnology to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
02 Juni 2021 - 10:05PM
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on
creating and delivering engineered cells as medicines, today
announced that it will webcast its presentation at the Goldman
Sachs 42nd Annual Global Healthcare Conference at 12:00 p.m. PT on
Wednesday, June 9, 2021. The presentation will feature a business
overview and update by Steve Harr, Sana’s President and Chief
Executive Officer.
The webcast will be accessible on the Investor Relations page of
Sana’s website at www.Sana.com. A replay of the presentation will
be available at the same location for 30 days following the
conference.
About Sana BiotechnologySana Biotechnology,
Inc. is focused on creating and delivering engineered cells as
medicines for patients. We share a vision of repairing and
controlling genes, replacing missing or damaged cells, and making
our therapies broadly available to patients. We are more than 280
people working together to create an enduring company that changes
how the world treats disease. Sana has operations in Seattle,
Cambridge, and South San Francisco. For more information about Sana
Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Sana Biotechnology, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to the Company’s vision, progress, and
business plans; expectations for its development programs, product
candidates and technology platforms, including its pre-clinical and
clinical and regulatory development plans and timing expectations;
Sana’s participation in the Goldman Sachs 42nd Annual Global
Healthcare Conference; and the subject matter of Sana’s
presentation at that conference. All statements other than
statements of historical facts contained in this press release,
including, among others, statements regarding the Company’s
strategy, expectations, cash runway and future financial condition,
future operations, and prospects, are forward-looking statements.
In some cases, you can identify forward-looking statements by
terminology such as “aim,” “anticipate,” “assume,” “believe,”
“contemplate,” “continue,” “could,” “design,” “due,” “estimate,”
“expect,” “goal,” “intend,” “may,” “objective,” “plan,”
“positioned,” “potential,” “predict,” “seek,” “should,” “target,”
“will,” “would” and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of
these terms or other comparable terminology. The Company has based
these forward-looking statements largely on its current
expectations, estimates, forecasts and projections about future
events and financial trends that it believes may affect its
financial condition, results of operations, business strategy and
financial needs. In light of the significant uncertainties in these
forward-looking statements, you should not rely upon
forward-looking statements as predictions of future events. These
statements are subject to risks and uncertainties that could cause
the actual results to vary materially, including, among others, the
risks inherent in drug development such as those associated with
the initiation, cost, timing, progress and results of the Company’s
current and future research and development programs, preclinical
and clinical trials, as well as the economic, market and social
disruptions due to the ongoing COVID-19 public health crisis. For a
detailed discussion of the risk factors that could affect the
Company’s actual results, please refer to the risk factors
identified in the Company’s SEC reports, including but not limited
to its Annual Report on Form 10-K dated March 24, 2021 and
Quarterly Report on Form 10-Q dated May 5, 2021. Except as required
by law, the Company undertakes no obligation to update publicly any
forward-looking statements for any reason.
Investor Relations:Nicole
Keithinvestor.relations@sana.com
Media:Morgan Warners, Finsbury Glover
Heringmedia@sana.com
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
Von Jul 2023 bis Jul 2024